These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 19439771)

  • 1. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
    Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
    Bukowski RM
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):25-8. PubMed ID: 16773842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based urology in practice: when to believe a subgroup analysis?
    Wang SS; Ou YC; Cheng CL; Dahm P;
    BJU Int; 2010 Jan; 105(2):162-4. PubMed ID: 19912181
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.
    de Sahb-Berkovitch R; Woronoff-Lemsi MC; Molimard M;
    Therapie; 2010; 65(4):373-7, 367-72. PubMed ID: 20854761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical results of Nexavar for the treatment of kidney cancer].
    Escudier B
    Prog Urol; 2007 Feb; 17(1 Suppl 1):150-3. PubMed ID: 17571640
    [No Abstract]   [Full Text] [Related]  

  • 7. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation in clinical nephrology: part 2. Applying economic evaluations in clinical nephrology.
    Wong G; Howard K; Craig JC
    Nephrology (Carlton); 2010 Aug; 15(5):533-9. PubMed ID: 20649872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Schizophrenic patients' length of stay: mental health care implication and medicoeconomic consequences].
    Capdevielle D; Boulenger JP; Villebrun D; Ritchie K
    Encephale; 2009 Sep; 35(4):394-9. PubMed ID: 19748377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From a cancer drug fund to value based pricing of drugs.
    Duerden M
    BMJ; 2010 Aug; 341():c4388. PubMed ID: 20705656
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
    Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
    Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic kidney disease in the United States: a public policy imperative.
    Rettig RA; Norris K; Nissenson AR
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1902-10. PubMed ID: 18922986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.
    Elsada A; Adler AI
    Lancet Oncol; 2017 Sep; 18(9):1153-1154. PubMed ID: 28800862
    [No Abstract]   [Full Text] [Related]  

  • 17. Biostatistical aspects for the use of evidence based medicine in health technology assessment.
    Freemantle N
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():31-43. PubMed ID: 18987906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postacute rehabilitation research and policy recommendations.
    Clohan DB; Durkin EM; Hammel J; Murray P; Whyte J; Dijkers M; Gans BM; Graves DE; Heinemann AW; Worsowicz G
    Arch Phys Med Rehabil; 2007 Nov; 88(11):1535-41. PubMed ID: 17964901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.